United Health Products Faces FDA Hurdle While Pursuing OTCQB Uplisting

United Health Products (UEEC) has successfully transitioned to the OTCQB Venture Market, a significant milestone for the medical technology company seeking to expand its investor base and market visibility. The uplisting, effective May 1, 2025, represents an important step in the company's strategic development, potentially improving stock liquidity and attracting a broader range of investors.

However, the company simultaneously faces a regulatory challenge with the Food and Drug Administration (FDA) regarding its Investigational Device Exemption (IDE) application for its CelluSTAT Hemostatic Gauze. The FDA declined to approve the clinical study application, not due to design deficiencies, but based on findings from Bioresearch Monitoring (BIMO) audits conducted in the third quarter of 2024.

Chief Executive Officer Brian Thom emphasized the uplisting as a reflection of the company's commitment to transparency and corporate growth. The OTCQB platform, recognized by the SEC as an established public market, requires companies to maintain current financial reporting and undergo annual verification processes.

The pending FDA issue centers on audit findings from UHP's 2019 clinical study. Despite the company's responses to the FDA on October 25, 2024, and April 14, 2025, the regulatory agency has not yet approved the follow-on clinical study. UHP is scheduling a teleconference within the next 10 days, hoping to resolve the outstanding concerns and proceed with their clinical research.

The hemostatic gauze product, developed as an all-natural solution for controlling mild to moderate bleeding, remains a critical focus for United Health Products. The company continues to advance preparatory clinical study tasks while awaiting IDE approval, demonstrating resilience in the face of regulatory challenges.

Investors and industry observers should note that while the OTCQB uplisting provides increased market legitimacy, the FDA approval process remains uncertain. The company's ability to navigate these regulatory complexities will be crucial in determining its future success in accessing the human surgical market.